Washington, D.C. 20549

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)

(Date of Event Which Requires Filing of this Statement)

 

 

CUSIP No.		12619C101

CUSIP No.

ITEM 1. SECURITY AND ISSUER

This Schedule 13D (this “Schedule 13D”) relates to the common stock, par value $.001 per share (the “Common Stock”) of CNS Response, Inc., a Delaware corporation (the “Company”), which has its principal executive offices at 2775 Bristol St., Costa Mesa, California 92626.

ITEM 2. IDENTITY AND BACKGROUND

This Schedule 13D is being filed by jointly by Leonard Brandt, a citizen of the United States (“Brandt”) and Meyerlen LP, a Minnesota limited partnership (“Meyerlen”). The present principal occupation of Brandt is serving as a director of the Company. The principal business address of Brandt is 28911 Via Hacienda, San Juan Capistrano, California 92675. Meyerlen is not engaged in any business. Leonard Brandt is the General Partner of Meyerlen, and in this capacity exercises voting and dispositive power over the securities held by this entity.

During the last five years, neither Brandt nor Meyerlen has been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) or been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

On June 9, 2009, Brandt paid the Company $6,709 of his personal funds to exercise warrants to purchase Common Stock held by Brandt.

On June 19, 2009, Brandt paid the Company $280,465.70 of his personal funds to exercise warrants and options to purchase Common Stock held by Brandt.

ITEM 4. PURPOSE OF TRANSACTION.

Reference is made to the disclosure set forth under Item 3 of this Schedule 13D, which disclosure is incorporated herein by reference.

All of the information in this Schedule is given as of June 26, 2009 and is based on Brandt’s belief that 28,349,171 shares of Common Stock are issued and outstanding.

All of the 7,934,631 shares of Common Stock (including the 540,000 share which are owned by Brandt’s children) held by Brandt, and to which this Schedule 13D relates, are held by Brandt and his children as an investment and the shares held by Brandt are also held in connection with the purposes described below. Brandt disclaims beneficial ownership of his children’s shares.

Brandt and Meyerlen beneficially own 28.0% and 0%, respectively, of the issued and outstanding shares of Common Stock of the Company, which is the only class of voting security which the Company has issued and outstanding as of the date hereof.

Brandt intends to change the entire Board of Directors of the Company, with the exception of the reelection of Brandt. Brandt has called a special meeting of stockholders of the Company, in lieu of an annual meeting of stockholders, and intends to cause that meeting to be held in order to conduct an election of directors of the Company at which Brandt intends to nominate and to vote in favor of a slate of directors selected by Brandt. Brandt also intends, in the alternative, to present the Company with written consents of stockholders of the Company to remove the current Board, with the exception of Brandt, and to elect as directors the slate of nominees selected by Brandt. Also, Brandt plans to propose to that new Board, if and when elected, that it should consider and vote on whether to adopt other changes in management of the Company, whether to scale-back or change current budgets and spending plans, whether to proceed with current Company business strategies, whether to proceed with current Company financing strategies that likely will include sales of securities of the Company, whether to modify current Company plans on these subjects and whether to adopt alternative plans on these subjects.

Brandt made a loan of $250,000 to the Company with his personal funds, and such loan is evidenced by a promissory note that may become convertible into securities of the Company in the event the Company completes an offering and sale of equity securities in a specified minimum amount. The promissory note is not presently convertible, and the promissory note may not become convertible during the next 60 days. The conversion price is

unknown and will be based upon the future sales price, if any, in the qualified offering. Brandt disclaims beneficial ownership of these securities. At some future time, Brandt may acquire securities of the Company under the terms of this promissory note.

Brandt has received from seven (7) stockholders their consents in writing authorizing the removal of the current directors and the election of a slate of directors selected by Brandt. Those consents relate to 5,486,274 shares of Common Stock, which constitute approximately 19.4% of the outstanding Common Stock. Brandt disclaims beneficial ownership of those shares. Brandt also disclaims that Brandt and those stockholders are members of a group, as the stockholders have not agreed to act together for the purpose of acquiring, holding, voting or disposing of equity securities of the Company and each consent is revocable in the sole discretion of the respective stockholder. Brandt intends to participate as an investor in future offerings of the Company.

Other than as expressly described in this Schedule 13D, neither Brandt nor Meyerlen has any plans or proposals which would result in the acquisition by any person of additional securities of the Company or the disposition of securities of the Company; any extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Company or any of its subsidiaries; a sale or transfer of a material amount of assets of the Company or any of its subsidiaries; any change in the present board of directors or management of the Company, including any place or proposals to change the number or term of directors or to fill any existing vacancies on the Company’s Board; any material change in the present capitalization or dividend policy of the Company; any other material change in the Company’s business or corporate structure; any changes in Company’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Company by any person; causing a class of securities of the Company to be delisted from national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; a class of equity securities of the Company becoming eligible for termination of registration pursuant to section 12(g)(4) of the Act; or any action similar to any of those enumerated above.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

Reference is made to the disclosure set forth under Items 3 and 4 of this Schedule 13D, which disclosure is incorporated herein by reference.

As of June 26, 2009, Brandt beneficially owned 7,934,631 shares of Common Stock, including for this purpose the 540,000 shares which are owned by Brandt’s children (collectively, the “Brandt Shares”). Assuming a total of 28,349,171 shares of the Company’s Common Stock outstanding as of June 19, 2009, the Brandt Shares constitute approximately 28.0% of the shares of the Company’s Common Stock issued and outstanding. Brandt has the sole power to vote and dispose of 7,394,631 of the Brandt Shares, and the remaining 540,000 shares are owned by his children, who have sole voting and dispositive power over those shares.

As of June 26, 2009, Meyerlen beneficially owned no shares of the Company’s Common Stock, constituting 0% of the shares of the Company’s Common Stock issued and outstanding. The shares of Common Stock and warrants to purchase Common Stock that were previously owned were distributed to Brandt more than 60 days before this filing.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS WITH RESPECT TO SECURITIES OF THE ISSUER

Not applicable.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

Exhibit
No.
	1			Joint Filing Agreement.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

EXHIBIT INDEX

Exhibit
No.
1*		Joint Filing Agreement.